Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anticoagulation vs Aspirin After TAVI
2023-510211-20-00Phase 3Completed
- Sponsor
- Oslo University Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rivaroxaban, apixaban, edoxaban and aspirin in aortic stenosis (AS) and aortic valve disease (AVD) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Hypo-attenuated leaflet thickening and Safety composite (non-inferiority). Started Oct 2024; status: completed.
02
Drugs
rivaroxabanapixabanedoxabanaspirin
03
Conditions
aortic stenosis (AS)aortic valve disease (AVD)
Beyond the preview
Go deeper on 2023-510211-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510211-20-00.